Caplin Point Laboratories Limited has informed the Exchange regarding a press release dated Jun 12, 2023, titled "Press Release regarding grant of United States Food and Drug Administration (USFDA) approval for the Abbreviated New Drug Application (ANDA) Cisatracurium Besylate Injection USP for our subsidiary Caplin Steriles Limited".